Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2016
17th World Conference on Lung Cancer
Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria
Presentation Date(s):- Dec 4 - 7, 2016
- Total Presentations: 2466
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
P1.03 - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Radiology/Staging/Screening
- Presentations: 84
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.03-025 - Serum KL-6 Levels in Patients with Lung Cancer
14:30 - 14:30 | Author(s): T. Yoshimasu
- Abstract
Loading...
-
+
OA08 - Targeted Therapies in Brain Metastases
- Type: Oral Session
- Track: Advanced NSCLC
- Presentations: 8
- Moderators:D. Ball
- Coordinates: 12/05/2016, 16:00 - 17:30, Schubert 1
-
+
OA08.06 - Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials
16:55 - 17:05 | Author(s): S.N. Gettinger
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
SC11 - ALK, ROS1 and Rare Mutations in NSCLC
- Type: Science Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 5
- Moderators:D. Kim
- Coordinates: 12/05/2016, 16:00 - 17:30, Lehar 1-2
-
+
SC11.02 - Resistance to ALK Inhibitor Therapy
16:20 - 16:40 | Author(s): S. Ou
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA07 - ALK-ROS1 in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:N. Singh
- Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 1-2
-
+
MA07.02 - Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer
11:06 - 11:12 | Author(s): D..R. Camidge
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA08 - Treatment Monitoring in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:R. Perez-Soler
- Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 3-4
-
+
MA08.01 - A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
11:00 - 11:06 | Author(s): H. Wakelee
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA10 - EGFR Mutations
- Type: Oral Session
- Track: Biology/Pathology
- Presentations: 8
- Moderators:J. Spicer
- Coordinates: 12/06/2016, 11:00 - 12:30, Strauss 1
-
+
OA10.01 - Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade
11:00 - 11:10 | Author(s): J.W. Riess
- Abstract
Loading...
-
+
MA14 - Immunotherapy in Advanced NSCLC: Biomarkers and Costs
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:M. Reck
- Coordinates: 12/06/2016, 16:00 - 17:30, Strauss 2
-
+
MA14.01 - Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC)
16:00 - 16:06 | Author(s): A.B. Schrock
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA16 - Novel Strategies in Targeted Therapy
- Type: Mini Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 12
- Moderators:G. Purkalne
- Coordinates: 12/07/2016, 14:20 - 15:50, Strauss 2
-
+
MA16.03 - Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers
14:26 - 14:32 | Author(s): O. Gautschi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA16.09 - Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
15:14 - 15:20 | Author(s): A. Drilon
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.02a - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 37
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02a-016 - Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC)
14:30 - 14:30 | Author(s): J.C. Yang
- Abstract
Loading...
-
+
P3.02c - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 103
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02c-014 - Patients with Recurrence after Resection of Lung Cancer Are Good Candidates for the beyond over Progressive Disease Application of Bevacizumab
14:30 - 14:30 | Author(s): T. Yoshimasu
- Abstract
Loading...